AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24843430 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factor - Systolic blood pressure
Number of subjects: 1806
Study 24843430 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factor - High-sensitivity C-reactive protein (hsCRP)
Number of subjects: 1806
Study 24843430 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factor - Triglyceride
Number of subjects: 1806
Study 24843430 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factor - Waist-to-hip ratio (after excluding IFG and IGT)
Number of subjects: 1806
Study 17764606 — intervention group
Group type: EXPERIMENTAL
Intervention: Free iron/folic acid tablets (treatment, n = 109)
Number of subjects: 221
Study 17764606 — intervention group
Group type: COMPARATOR
Intervention: Prescription to purchase iron/folic acid tablets (control, n = 112)
Number of subjects: 221
Study 17126666 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 300 mg
Number of subjects: 20
Study 17126666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15238038 — intervention group
Group type: EXPERIMENTAL
Intervention: Moving to low-poverty neighborhoods
Number of subjects: 588
Study 11411812 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline treatment during the 24-week open-label continuation phase
Number of subjects: 128
Study 9827122 — intervention group
Group type: EXPERIMENTAL
Intervention: Local solution based on 'pain de singe' (baobab fruit)
Number of subjects: 161
Study 9827122 — intervention group
Group type: COMPARATOR
Intervention: WHO standard solution
Number of subjects: 161
Study 8314474 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 million units (MU) interferon three times weekly for six months
Number of subjects: 111
Study 8314474 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 MU interferon three times weekly for the first six months, 2 MU for the next three months, and 1 MU for the last three months
Number of subjects: 111
Study 8314474 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without cirrhosis
Number of subjects: 111
Study 8314474 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with cirrhosis
Number of subjects: 111
Study 8314474 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer treatment (12 months)
Number of subjects: 111
Study 8314474 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter treatment (6 months)
Number of subjects: 111
Study 3555164 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine plus 1 ml normal saline (Group I)
Number of subjects: 60
Study 3555164 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine plus 0.2 mg epinephrine (Group II)
Number of subjects: 60
Study 3555164 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine plus 0.15 mg clonidine (Group III)
Number of subjects: 60
Study 30724035 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 123
Study 30724035 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 123
Study 30007057 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg orally 2 hours before surgery and 150 mg at 12 and 24 hours after surgery
Number of subjects: 60
Study 30007057 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 60
Study 27511183 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine transporter imaging
Number of subjects: 187
Study 27511183 — intervention group
Group type: COMPARATOR
Intervention: Follow-up without scan
Number of subjects: 187
Study 24646327 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 lymphadenectomy performed by qualified surgeons
Number of subjects: 0
Study 24646327 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeons' laparoscopic and open D2 gastrectomy videos
Number of subjects: 0
Study 22972030 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 30 mg once daily
Number of subjects: 32
Study 22972030 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 7.5 mg once daily
Number of subjects: 32
Study 22972030 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion (plasma insulin 200 pmol/l)
Number of subjects: 32
Study 22972030 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion (plasma insulin 600 pmol/l)
Number of subjects: 32
Study 22972030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 19819661 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified smoking cessation treatment for depressive smokers
Number of subjects: 268
Study 19819661 — intervention group
Group type: COMPARATOR
Intervention: Standard smoking cessation treatment
Number of subjects: 268
Study 19819661 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified smoking cessation treatment for higher dependence smokers
Number of subjects: 268
Study 17211088 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg monthly ibandronate
Number of subjects: 228
Study 17211088 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg bi‐monthly ibandronate
Number of subjects: 228
Study 17211088 — intervention group
Group type: EXPERIMENTAL
Intervention: All ibandronate regimens
Number of subjects: 228
Study 17211088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 228
Study 15911865 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin 50 mg/m(2) every 3 weeks (CPT)
Number of subjects: 294
Study 15911865 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 50 mg/m(2) day 1 plus topotecan 0.75 mg/m(2) days 1 to 3 every 3 weeks (CT)
Number of subjects: 294
Study 12479047 — intervention group
Group type: EXPERIMENTAL
Intervention: Epristeride 5 mg p.o., twice daily for 120 days
Number of subjects: 141
Study 10681767 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenmai liquid and improved St. Thomas Crystal Blood (1:4) Cardioplegia (Group B)
Number of subjects: 40
Study 10681767 — intervention group
Group type: COMPARATOR
Intervention: Improved St. Thomas Crystal Blood (1:4) Cardioplegia (Group A)
Number of subjects: 40
Study 7622826 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (100‐300 mg/day)
Number of subjects: 315
Study 2533526 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafarelin (200 micrograms twice daily intranasally for 3 or 6 months)
Number of subjects: 15
Study 6359 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg
Number of subjects: 0
Study 6359 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 25 mg
Number of subjects: 0
Study 6359 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg
Number of subjects: 0
Study 6359 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 0
Study 31303080 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling (four sessions covering medical information about EP, sadness syndrome, mental health improvement, and self-esteem enhancement)
Number of subjects: 68
Study 31303080 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 68
Study 31078943 — intervention group
Group type: EXPERIMENTAL
Intervention: tRNS applied for 20 min at a current strength of 2 mA during practice blocks
Number of subjects: 34
Study 31078943 — intervention group
Group type: COMPARATOR
Intervention: SHAM stimulation during practice blocks
Number of subjects: 34
Study 28065704 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-anchored expander
Number of subjects: 61
Study 28065704 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth-borne maxillary expander (Hyrax)
Number of subjects: 61
Study 28065704 — intervention group
Group type: COMPARATOR
Intervention: Untreated (Control)
Number of subjects: 61
Study 26087654 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX plus adalimumab (ADA)
Number of subjects: 151
Study 26087654 — intervention group
Group type: COMPARATOR
Intervention: MTX plus placebo-ADA (PLA)
Number of subjects: 151
Study 23475016 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia-based training
Number of subjects: 70
Study 23475016 — intervention group
Group type: EXPERIMENTAL
Intervention: Practical training
Number of subjects: 70
Study 23475016 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination training (multimedia-based training + practical training)
Number of subjects: 70
Study 23475016 — intervention group
Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 70
Study 21690484 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 19
Study 21690484 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 19
Study 19553301 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 g oil-rich fish (salmon) per week (n = 82)
Number of subjects: 242
Study 19553301 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 g lean fish (cod) per week (n = 78)
Number of subjects: 242
Study 19553301 — intervention group
Group type: COMPARATOR
Intervention: Dietary advice (DA) (n = 82)
Number of subjects: 242
Study 17548749 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline plus liothyronine
Number of subjects: 124
Study 17548749 — intervention group
Group type: COMPARATOR
Intervention: Sertraline plus placebo
Number of subjects: 124
Study 15485729 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepayment cash incentive of HK dollar 20, n=474
Number of subjects: 949
Study 15485729 — intervention group
Group type: COMPARATOR
Intervention: Postpayment cash incentive of HK dollar 20, n=475
Number of subjects: 949
Study 11584755 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 266
Study 11584755 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine (AQ)
Number of subjects: 266
Study 11584755 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine + Pyrimethamine (SP)
Number of subjects: 266
Study 11584755 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant infections
Number of subjects: 266
Study 11584755 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitive infections
Number of subjects: 266
Study 9591932 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg imidapril once per day for 7 days
Number of subjects: 24
Study 8164861 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ankle mobilization
Number of subjects: 0
Study 8164861 — intervention group
Group type: COMPARATOR
Intervention: Cast immobilization
Number of subjects: 0
Study 8164861 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 3363169 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical internal mammary chain dissection and post-operative irradiation
Number of subjects: 1195
Study 3363169 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative irradiation to the IMC, axilla, chest wall and supraclavicular nodes
Number of subjects: 1195
Study 3363169 — intervention group
Group type: COMPARATOR
Intervention: Control group (lateral tumors)
Number of subjects: 1195
Study 30536920 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational DVD (Gynecology: Beginners Only)
Number of subjects: 57
Study 30536920 — intervention group
Group type: COMPARATOR
Intervention: Routine education (Control)
Number of subjects: 57
Study 28241231 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone gel
Number of subjects: 211
Study 28241231 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 211
Study 25594526 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist protocol, programmed to start stimulatory agents on a Friday, with oral 2mg estradiol valerate twice a day from the 2nd day of cycle until the first Friday to follow.
Number of subjects: 51
Study 25594526 — intervention group
Group type: COMPARATOR
Intervention: Long luteal GnRH agonist protocol.
Number of subjects: 51
Study 25594526 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist protocol.
Number of subjects: 51
Study 25594526 — intervention group
Group type: COMPARATOR
Intervention: GnRH agonist protocol.
Number of subjects: 51
Study 23683980 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Action program
Number of subjects: 0
Study 21267037 — intervention group
Group type: EXPERIMENTAL
Intervention: SCS at subthreshold intensity (SCS80)
Number of subjects: 15
Study 21267037 — intervention group
Group type: EXPERIMENTAL
Intervention: SCS at threshold intensity (SCS100)
Number of subjects: 15
Study 21267037 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control, no SCS)
Number of subjects: 15
Study 21267037 — intervention group
Group type: EXPERIMENTAL
Intervention: SCS (both SCS80 and SCS100)
Number of subjects: 15
Study 19470941 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 150 mg/m(2) weekly
Number of subjects: 302
Study 19470941 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 100 mg/m(2) weekly
Number of subjects: 302
Study 19470941 — intervention group
Group type: COMPARATOR
Intervention: nab-paclitaxel q3w
Number of subjects: 302
Study 19470941 — intervention group
Group type: EXPERIMENTAL
Intervention: All nab-paclitaxel arms
Number of subjects: 302
Study 16950969 — intervention group
Group type: EXPERIMENTAL
Intervention: Special intervention (brief pediatric provider‐delivered intervention plus peer counseling)
Number of subjects: 2710
Study 16950969 — intervention group
Group type: COMPARATOR
Intervention: Usual care condition
Number of subjects: 2710
Study 15315622 — intervention group
Group type: EXPERIMENTAL
Intervention: A‐line ARX index (n = 50)
Number of subjects: 100
Study 15315622 — intervention group
Group type: COMPARATOR
Intervention: Bispectral index (n = 50)
Number of subjects: 100
Study 11333992 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (6.25 to 50 mg twice daily)
Number of subjects: 1094
Study 11333992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1094
Study 9284847 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol with 1.5 gm ammonium chloride (NH4Cl) four times daily for 3 days
Number of subjects: 15
Study 9284847 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol with 200 mg trimethoprim once daily for 3 days
Number of subjects: 15
Study 9284847 — intervention group
Group type: COMPARATOR
Intervention: Control (pindolol alone)
Number of subjects: 15
Study 7904188 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate with aspirin
Number of subjects: 24
Study 7904188 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 24
Study 7904188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 3554082 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation with 25,000 IU of retinol daily for up to 3 months
Number of subjects: 46
Study 3554082 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation with 50,000 IU of retinol daily for up to 3 months
Number of subjects: 46
Study 3554082 — intervention group
Group type: COMPARATOR
Intervention: Control group (no retinol supplementation)
Number of subjects: 46
Study 3554082 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of retinol supplementation
Number of subjects: 46
Study 29561524 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-s/projection SPECT
Number of subjects: 30
Study 29561524 — intervention group
Group type: COMPARATOR
Intervention: Native SPECT
Number of subjects: 30
Study 26707831 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-randomized trial design for mobile interventions
Number of subjects: 0
Study 26707831 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartSteps mobile application
Number of subjects: 0
Study 24156287 — intervention group
Group type: EXPERIMENTAL
Intervention: Lead-in statement suggesting high likelihood of hypertension
Number of subjects: 162
Study 24156287 — intervention group
Group type: EXPERIMENTAL
Intervention: Lead-in statement suggesting normality
Number of subjects: 162
Study 22615758 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation (experienced meditators)
Number of subjects: 0
Study 22615758 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight meeting mindfulness program (non-meditators)
Number of subjects: 0
Study 22615758 — intervention group
Group type: COMPARATOR
Intervention: Waiting list group (control)
Number of subjects: 0
Study 20386259 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic deconstructive psychotherapy (DDP)
Number of subjects: 30
Study 20386259 — intervention group
Group type: COMPARATOR
Intervention: Optimized community care (OCC)
Number of subjects: 30
Study 18476999 — intervention group
Group type: EXPERIMENTAL
Intervention: Test Brush group with a template slow‐delivery system of chlorhexidine (Ttb)
Number of subjects: 150
Study 18476999 — intervention group
Group type: COMPARATOR
Intervention: Control Brush group without CHX (Ctb)
Number of subjects: 150
Study 18476999 — intervention group
Group type: COMPARATOR
Intervention: Control Brush group without CHX but rinsing post‐brushing with a 0.2% CHX mouthrinse (Ctb+R)
Number of subjects: 150
Study 15922816 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol tartrate (BT) nasal spray 1 mg
Number of subjects: 60
Study 15922816 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol tartrate (BT) nasal spray 2 mg
Number of subjects: 60
Study 15922816 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 12524381 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (Cr)
Number of subjects: 33
Study 12524381 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine plus Protein (Cr+P)
Number of subjects: 33
Study 12524381 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 33
Study 12820740 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartMate vented electric LVAD implantation
Number of subjects: 129
Study 12820740 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical management
Number of subjects: 129
Study 7883742 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex
Number of subjects: 0
Study 7883742 — intervention group
Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 0
Study 7883742 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroshock therapy
Number of subjects: 0
Study 2568348 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (100 mg and 200 mg)
Number of subjects: 10
Study 2568348 — intervention group
Group type: EXPERIMENTAL
Intervention: D-amphetamine (10 mg and 20 mg)
Number of subjects: 10
Study 2568348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2568348 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 10
Study 2568348 — intervention group
Group type: EXPERIMENTAL
Intervention: D-amphetamine (20 mg)
Number of subjects: 10
Study 1053467 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 50
Study 1053467 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 50
Study 29770722 — intervention group
Group type: EXPERIMENTAL
Intervention: Desoximetasone 0.25% spray
Number of subjects: 0
Study 29770722 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone valerate 0.1% cream
Number of subjects: 0
Study 29770722 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide 0.1% ointment
Number of subjects: 0
Study 29770722 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluocinonide 0.05% gel
Number of subjects: 0
Study 29770722 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone valerate 0.1% lotion
Number of subjects: 0
Study 29770722 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate 0.05% foam
Number of subjects: 0
Study 29770722 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluocinonide 0.05% solution
Number of subjects: 0
Study 29770722 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall vehicle characteristics
Number of subjects: 0
Study 31127666 — intervention group
Group type: EXPERIMENTAL
Intervention: Reprieve therapy (with normal saline for matched volume replacement)
Number of subjects: 19
Study 31127666 — intervention group
Group type: COMPARATOR
Intervention: Standard diuretic therapy
Number of subjects: 19
Study 31127666 — intervention group
Group type: EXPERIMENTAL
Intervention: Reprieve therapy
Number of subjects: 19
Study 28581401 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippocampal-sparing prophylactic cranial irradiation (PCI) 25 Gy/10 fractions, with a mean hippocampal dose limited to <8 Gy.
Number of subjects: 20
Study 28581401 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippocampal-sparing prophylactic cranial irradiation (PCI)
Number of subjects: 20
Study 25832297 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalmefene
Number of subjects: 0
Study 25832297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23570586 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ) at 200 or 150 mg×m(‐2)d(‐1) for 5 days, repeated every 28 days
Number of subjects: 151
Study 23570586 — intervention group
Group type: COMPARATOR
Intervention: Semustine (Me‐CCNU) at 150 mg×m(‐2)×d(‐1) once, repeated every 28 days
Number of subjects: 151
Study 23570586 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ)
Number of subjects: 151
Study 23570586 — intervention group
Group type: COMPARATOR
Intervention: Semustine (Me‐CCNU)
Number of subjects: 151
Study 21677099 — intervention group
Group type: EXPERIMENTAL
Intervention: Molar bands (cemented with conventional glass ionomer cement)
Number of subjects: 80
Study 21677099 — intervention group
Group type: COMPARATOR
Intervention: Molar bonds (bonded with light-cured composite)
Number of subjects: 80
Study 21677099 — intervention group
Group type: COMPARATOR
Intervention: Molar bonds
Number of subjects: 80
Study 21677099 — intervention group
Group type: EXPERIMENTAL
Intervention: Molar bands and Molar bonds
Number of subjects: 80
Study 19201610 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task training with variable-priority (VP) instruction
Number of subjects: 0
Study 19201610 — intervention group
Group type: COMPARATOR
Intervention: Single-task (ST) balance training
Number of subjects: 0
Study 19201610 — intervention group
Group type: COMPARATOR
Intervention: Dual-task training with fixed-priority (FP) instruction
Number of subjects: 0
Study 16516059 — intervention group
Group type: EXPERIMENTAL
Intervention: IMPACT protocol (poststudy)
Number of subjects: 297
Study 16516059 — intervention group
Group type: COMPARATOR
Intervention: Usual care (historical control)
Number of subjects: 297
Study 15517847 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular ziprasidone
Number of subjects: 1005